HOME >> BIOLOGY >> NEWS
IC-medtech licenses promising cancer therapeutic from Summa Health System

(Akron, Ohio) In September 2001, researchers at Summa Health System in Akron, Ohio reported that moderate doses of the vitamins C and K3 were eliminating many types of cancer cells including prostate, bladder, renal and ovarian. Today, only three years later, the results of Summa's cancer research is being licensed and under a new name, ApatoneTM. Clinical trials of the drug could begin as soon as next month at Summa Health System and other hospitals across the nation.

Indian Creek Medical Technologies, LLC has exclusively licensed Apatone, the novel anti-cancer therapeutic treatment first discovered by James M. Jamison, Ph.D. and Jack L. Summers, M.D, Ph.D, both of Summa Health System, in collaboration with Jacques Gilloteaux, DSc, and Henryk Taper, M.D., Ph.D. of Brussels, Belgium. The Summa team has been working collaboratively with Gilloteaux and Taper for nine years conducting extensive experimentation and now Summers and Jamison are excited by this next step with IC-MedTech.

"What is so significant about our study is that through out research of cancer cells, we have discovered a new form of cell death, never before reported," said Summers.

"We found early on that the combination of vitamins C and K3 seek out tumor cells and appear to leave normal cells unaffected," Summers explained. "The dying cells undergo a new flow of self-destruction in which the cell literally cuts itself into small pieces. This discovery was the first of its kind and to this point, cells were considered to die only by apoptosis (programmed cell death) or necrosis (toxic cell death or injury.)"

According to Tom Miller, CEO of IC-MedTech, his company is excited about the possibilities this drug could bring to cancer patients. "The research is substantial and shows that Apatone leverages a novel mechanism of action that shows strong promise as a clinical candidate to be developed for a variety of cancers."


'"/>

Contact: Heather Phillips
philliph@summa-health.org
330-375-7930
Summa Health System
26-Oct-2004


Page: 1 2

Related biology news :

1. University of Colorado licenses two influenza virus detection discoveries to Quidel Corp.
2. Rensselaer licenses microscope technology to Thorlabs
3. Columbia University licenses next-generation DNA sequencing technology
4. Case Western Reserve University licenses methoxyamine to Tracon
5. Yale licenses potential anti-HIV agent to Oncolys BioPharma of Japan
6. Mount Sinai School of Medicine licenses avian flu vaccine to Avimex
7. Bayer HealthCare licenses Genomatix for microarray analysis
8. Isotron licenses ORNL cancer treatment technology
9. A new plant-bacterial symbiotic mechanism promising
10. A new plant-bacterial symbiotic mechanism promising for crop applications
11. American Association for Cancer Research provides support for promising cancer scientists

Post Your Comments:
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
(Date:5/28/2015)... 28, 2015 BioNorth Texas (BioNorthTX), ... representing the life sciences industry in northern region ... meeting at The Foundry in Dallas on April ... brought together a broad spectrum of biotech professionals ... organization's early successes in partnering with key life ...
(Date:5/28/2015)... Mass. , May 28, 2015 RXi ... focused on discovering and developing innovative therapeutics, primarily in ... pricing of a public offering of 26 million units ... share for gross proceeds of approximately $10.4 million. Each ... (ii) a 13-month overallotment purchase right to purchase 0.50 ...
(Date:5/28/2015)... Md. , May 28, 2015  GenVec, Inc. ... and CEO, Douglas J. Swirsky , will present ... Conference at 11 a.m. EDT on Thursday, June 4, ... of Mr. Swirsky,s presentation will be available at the ... be available on GenVec,s website.  To access, visit ...
(Date:5/28/2015)... 28, 2015 The Fertility Centers of ... Dr. Danielle Vitiello has taken on a new and ... Vitiello will provide guidance, leadership, oversight and quality assurance ... Dr. Vitiello among our team of experienced reproductive endocrinologists,” ... Joseph A. Hill, M.D. “Her expertise and compassionate, individualized ...
Breaking Biology Technology:BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
Cached News: